Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice

Neuroscience

Volumn 290, Issue , 2015, Pages 214-226

  Zhang, P ^a   Xie, M Q ^a   Ding, Y Q ^a   Liao, M ^a   Qi, S S ^b   Chen, S X ^a   Gu, Q Q ^a   Zhou, P ^a   Sun, C Y ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Allopregnanolone; Alzheimer's disease; APPswe PSEN1 mouse; Dopaminergic neuron; Neurogenesis; Substantia nigra pars compacta

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; AMYLOID BETA PROTEIN; BROXURIDINE; DOUBLECORTIN; NEURON SPECIFIC NUCLEAR PROTEIN; TYROSINE 3 MONOOXYGENASE; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; ELTANOLONE; NOOTROPIC AGENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MESENCEPHALON; MOUSE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NONHUMAN; SINGLE DRUG DOSE; STEM CELL NICHE; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; SUBVENTRICULAR ZONE; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; LATERAL BRAIN VENTRICLE; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PLAQUE, AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; LATERAL VENTRICLES; MALE; MESENCEPHALON; MICE, TRANSGENIC; MUTATION; NEURAL STEM CELLS; NEUROGENESIS; NOOTROPIC AGENTS; PLAQUE, AMYLOID; PREGNANOLONE; PRESENILIN-1; TYROSINE 3-MONOOXYGENASE;

EID: 84922683512     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.01.019     Document Type: Article

References (84)

1. Arias-Carrion O., Yamada E., Freundlieb N., Djufri M., Maurer L., Hermanns G., Ipach B., Chiu W.H., Steiner C., Oertel W.H., Höglinger G.U. Neurogenesis in substantia nigra of parkinsonian brains?. J Neural Transm Suppl 2009, 279-285.
2. Assal F., Cummings J.L. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2001, 15:445-450.
3. Baulieu E.E., Robel P., Schumacher M. Neurosteroids: beginning of the story. Int Rev Neurobiol 2001, 46:1-32.
4. Belelli D., Herd M.B., Mitchell E.A., Peden D.R., Vardy A.W., Gentet L., Lambert J.J. Neuroactive steroids and inhibitory neurotransmission: mechanisms of action and physiological relevance. Neuroscience 2006, 138:821-829.
5. Berg D.A., Kirkham M., Wang H., Frisen J., Simon A. Dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. Cell Stem Cell 2011, 8:426-433.
6. Berg D.A., Kirkham M., Beljajeva A., Knapp D., Habermann B., Ryge J., Tanaka E.M., Simon A. Efficient regeneration by activation of neurogenesis in homeostatically quiescent regions of the adult vertebrate brain. Development 2010, 137:4127-4134.
7. Burns J.M., Galvin J.E., Roe C.M., Morris J.C., McKeel D.W. The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs. Neurology 2005, 64:1397-1403.
8. Charalampopoulos I., Remboutsika E., Margioris A.N., Gravanis A. Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab 2008, 19:300-307.
9. Chen S., Wang J.M., Irwin R.W., Yao J., Liu L., Brinton R.D. Allopregnanolone promotes regeneration and reduces beta-amyloid burden in a preclinical model of Alzheimer's disease. PLoS One 2011, 6:e24293.
10. Chevallier N.L., Soriano S., Kang D.E., Masliah E., Hu G., Koo E.H. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am J Pathol 2005, 167:151-159.
11. Clinton L.K., Blurton-Jones M., Myczek K., Trojanowski J.Q., LaFerla F.M. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010, 30:7281-7289.
12. Coskun V., Wu H., Blanchi B., Tsao S., Kim K., Zhao J., Biancotti J.C., Hutnick L., Krueger R.C., Fan G., de Vellis J., Sun Y.E. CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci USA 2008, 105:1026-1031.
13. Dahlström A., Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964, 20:398-399.
14. Demars M., Hu Y.S., Gadadhar A., Lazarov O. Impaired neurogenesis is an early event in the etiology of familial Alzheimer's disease in transgenic mice. J Neurosci Res 2010, 88:2103-2117.
15. di Michele F., Longone P., Romeo E., Lucchetti S., Brusa L., Pierantozzi M., Bassi A., Bernardi G., Stanzione P. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol Sci 2003, 24:172-173.
16. Ditter S.M., Mirra S.S. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987, 37:754-760.
17. Ermini F.V., Grathwohl S., Radde R., Yamaguchi M., Staufenbiel M., Palmer T.D., Jucker M. Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. Am J Pathol 2008, 172:1520-1528.
18. Ewers M., Morgan D.G., Gordon M.N., Woodruff-Pak D.S. Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiol Aging 2006, 27:1118-1128.
19. Franklin K., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press, New York.
20. Gago N., El-Etr M., Sananes N., Cadepond F., Samuel D., Avellana-Adalid V., Baron-Van Evercooren A., Schumacher M. 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res 2004, 78:770-783.
21. Genazzani A.R., Petraglia F., Bernardi F., Casarosa E., Salvestroni C., Tonetti A., Nappi R.E., Luisi S., Palumbo M., Purdy R.H., Luisi M. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab 1998, 83:2099-2103.
22. Gibb W., Mountjoy C., Mann D., Lees A. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry 1989, 52:193-200.
23. Hattiangady B., Shetty A.K. Aging does not alter the number or phenotype of putative stem/progenitor cells in the neurogenic region of the hippocampus. Neurobiol Aging 2008, 29:129-147.
24. Hattiangady B., Rao M.S., Shetty G.A., Shetty A.K. Brain-derived neurotrophic factor, phosphorylated cyclic AMP response element binding protein and neuropeptide Y decline as early as middle age in the dentate gyrus and CA1 and CA3 subfields of the hippocampus. Exp Neurol 2005, 195:353-371.
25. Hermann A., Maisel M., Wegner F., Liebau S., Kim D.W., Gerlach M., Schwarz J., Kim K.S., Storch A. Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons. Stem Cells 2006, 24:949-964.
26. Höglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., Hirsch E.C. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004, 7:726-735.
27. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., Gonzalez M.I. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res 2004, 1017:130-136.
28. Jagasia R., Steib K., Englberger E., Herold S., Faus-Kessler T., Saxe M., Gage F.H., Song H., Lie D.C. GABA-cAMP response element-binding protein signaling regulates maturation and survival of newly generated neurons in the adult hippocampus. J Neurosci 2009, 29:7966-7977.
29. Kazee A.M., Cox C., Richfield E.K. Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis Assoc Disord 1995, 9:61-67.
30. Kazee A.M., Han L.Y. Cortical Lewy bodies in Alzheimer's disease. Arch Pathol Lab Med 1995, 119:448-453.
31. Keller E.A., Zamparini A., Borodinsky L.N., Gravielle M.C., Fiszman M.L. Role of allopregnanolone on cerebellar granule cells neurogenesis. Brain Res Dev Brain Res 2004, 153:13-17.
32. Kim H.D., Tahara K., Maxwell J.A., Lalonde R., Fukuiwa T., Fujihashi K., Van Kampen K.R., Kong F.K., Tang D.C., Fukuchi K. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med 2007, 9:88-98.
33. Kishimoto Y., Suzuki M., Kawahara S., Kirino Y. Age-dependent impairment of delay and trace eyeblink conditioning in mice. NeuroReport 2001, 12:3349-3352.
34. Klein W.L., Stine W.B., Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 2004, 25:569-580.
35. Klein W.L., Krafft G.A., Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci 2001, 24:219-224.
36. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
37. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., Rowan M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005, 11:556-561.
38. Kulkarni A.P., Pillay N.S., Kellaway L.A., Kotwal G.J. Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. Biogerontology 2008, 9:405-420.
39. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets 2003, 4:97-112.
40. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95:6448-6453.
41. Laplagne D.A., Espósito M.S., Piatti V.C., Morgenstern N.A., Zhao C., van Praag H., Gage F.H., Schinder A.F. Functional convergence of neurons generated in the developing and adult hippocampus. PLoS Biol 2006, 4:e409.
42. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
43. Liu Y., Stern Y., Chun M.R., Jacobs D.M., Yau P., Goldman J.E. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997, 41:368-374.
44. Lopez O.L., Wisnieski S.R., Becker J.T., Boller F., DeKosky S.T. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997, 54:969-975.
45. Lowe J., Lennox G., Leigh P. Disorders of movement and system degenerations. Greenfield's neuropathology 1997, vol. 2:281-366. Arnold & Oxford University Press, New York. 6th ed.
46. Luchetti S., Bossers K., Frajese G.V., Swaab D.F. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 2010, 20:945-951.
47. Marx C.E., Trost W.T., Shampine L.J., Stevens R.D., Hulette C.M., Steffens D.C., Ervin J.F., Butterfield M.I., Blazer D.G., Massing M.W., Lieberman J.A. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 2006, 60:1287-1294.
48. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Mucke L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001, 98:12245-12250.
49. Minturn J.E., Geschwind D.H., Fryer H.J., Hockfield S. Early postmitotic neurons transiently express TOAD-64, a neural specific protein. J Comp Neurol 1995, 355:369-379.
50. Morris J.C., Drazner M., Fulling K., Grant E.A., Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease: a role for extranigral factors?. Arch Neurol 1989, 46:651-657.
51. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottleib G.L., Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995, 37:300-312.
52. Naylor J.C., Kilts J.D., Hulette C.M., Steffens D.C., Blazer D.G., Ervin J.F., Strauss J.L., Allen T.B., Massing M.W., Payne V.M., Youssef N.A., Shampine L.J., Marx C.E. Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects. Biochim Biophys Acta 2010, 1801:951-959.
53. Niidome T., Taniuchi N., Akaike A., Kihara T., Sugimoto H. Differential regulation of neurogenesis in two neurogenic regions of APPswe/PS1dE9 transgenic mice. NeuroReport 2008, 19:1361-1364.
54. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Rozovsky I., Stine W.B., Snyder S.W., Holzman T.F. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 1995, 136:22-31.
55. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43:321-332.
56. Parihar M.S., Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 2004, 11:456-467.
57. Parish C.L., Beljajeva A., Arenas E., Simon A. Midbrain dopaminergic neurogenesis and behavioural recovery in a salamander lesion-induced regeneration model. Development 2007, 134:2881-2887.
58. Peng J., Andersen J.K. Mutant alpha-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Aging Cell 2011, 10:255-262.
59. Peng J., Oo M.L., Andersen J.K. Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. J Neurochem 2010, 115:1363-1373.
60. Peng J., Xie L., Jin K., Greenberg D.A., Andersen J.K. Fibroblast growth factor 2 enhances striatal and nigral neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience 2008, 153:664-670.
61. Perez S.E., Lazarov O., Koprich J.B., Chen E.Y., Rodriguez-Menendez V., Lipton J.W., Sisodia S.S., Mufson E.J. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 transgenic mice. J Neurosci 2005, 25:10220-10229.
62. Pugha P.L., Richardson J.C., Bate S.T., Upton N., Sunter D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res 2007, 178:18-28.
63. Rao M.S., Hattiangady B., Abdel-Rahman A., Stanley D.P., Shetty A.K. Newly born cells in the ageing dentate gyrus display normal migration, survival and neuronal fate choice but endure retarded early maturation. Eur J Neurosci 2005, 21:464-476.
64. Rodríguez J.J., Jones V.C., Tabuchi M., Allan S.M., Knight E.M., LaFerla F.M., Oddo S., Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 2008, 3:e2935.
65. Rodríguez J.J., Jones V.C., Verkhratsky A. Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model. NeuroReport 2009, 20:907-912.
66. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., Akwa Y., Rajkowski K., Baulieu E.E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007, 28:387-439.
67. Selkoe D.J. Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001, 3:75-80.
68. Shan X., Chi L., Bishop M., Luo C., Lien L., Zhang Z., Liu R. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice. Stem Cells 2006, 24:1280-1287.
69. Singh C., Liu L., Wang J.M., Irwin R.W., Yao J., Chen S., Henry S., Thompson R.F., Brinton R.D. Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging 2012, 33:1493-1506.
70. Steiner B., Wolf S., Kempermann G. Adult neurogenesis and neurodegenerative disease. Regen Med 2006, 1:15-28.
71. Sun C.Y., Ou X., Farley J.M., Stockmeier C., Bigler S., Brinton R.D., Wang J.M. Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of triple transgenic mouse model of alzheimer's disease. Curr Alzheimer Res 2012, 9:473-480.
72. Taniuchi N., Niidome T., Goto Y., Akaike A., Kihara T., Sugimoto H. Decreased proliferation of hippocampal progenitor cells in APPswe/PS1dE9 transgenic mice. NeuroReport 2007, 18:1801-1805.
73. Uchihara T., Kondo H., Kosaka K., Tsukagoshi H. Selective loss of nigral neurons in Alzheimer's disease: a morphometric study. Acta Neuropathol 1992, 83:271-276.
74. Valente T., Hidalgo J., Bolea I., Ramirez B., Anglés N., Reguant J., Morelló J.R., Gutiérrez C., Boada M., Unzeta M. A diet enriched in polyphenols and polyunsaturated fatty acids, LMN diet, induces neurogenesis in the subventricular zone and hippocampus of adult mouse brain. J Alzheimers Dis 2009, 18:849-865.
75. Verret L., Jankowsky J.L., Xu G.M., Borchelt D.R., Rampon C. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci 2007, 27:6771-6780.
76. Walters T.L., Irwin I., Delfani K., Langston J.W., Janson A.M. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 1999, 156:62-70.
77. Wang J.M. Allopregnanoloneandneurogenesisin thenigrostriataltract. Front Cell Neurosci 2014, 8:1-8.
78. Wang J.M., Singh C., Liu L., Irwin R.W., Chen S., Chung E.J., Thompson R.F., Brinton R.D. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2010, 107:6498-6503.
79. Wang J.M., Brinton R.D. Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci 2008, 9(Suppl. 2):S2-S11.
80. Wang J.M., Johnston P.B., Ball B.G., Brinton R.D. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 2005, 25:4706-4718.
81. Weill-Engerer S., David J.P., Sazdovitch V., Liere P., Eychenne B., Pianos A., Schumacher M., Delacourte A., Baulieu E.E., Akwa Y. Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab 2002, 87:5138-5143.
82. Zhang C., McNeil E., Dressler L., Siman R. Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease. Exp Neurol 2007, 204:77-87.
83. Zhao M., Janson Lang A.M. Bromodeoxyuridine infused into the cerebral ventricle of adult mice labels nigral neurons under physiological conditions-a method to detect newborn nerve cells in regions with a low rate of neurogenesis. J Neurosci Meth 2009, 184:327-331.
84. Zhao M., Momma S., Delfani K., Carlen M., Cassidy R.M., Johansson C.B., Brismar H., Shupliakov O., Frisen J., Janson A.M. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 2003, 100:7925-7930.